ADAG
Price
$1.99
Change
+$0.23 (+13.07%)
Updated
Jun 6 closing price
Capitalization
93.75M
81 days until earnings call
DOSEF
Price
$0.36
Change
-$0.02 (-5.26%)
Updated
Jun 4 closing price
Capitalization
1.63M
Interact to see
Advertisement

ADAG vs DOSEF

Header iconADAG vs DOSEF Comparison
Open Charts ADAG vs DOSEFBanner chart's image
Adagene
Price$1.99
Change+$0.23 (+13.07%)
Volume$73.12K
Capitalization93.75M
Doseology Sciences
Price$0.36
Change-$0.02 (-5.26%)
Volume$3.05K
Capitalization1.63M
ADAG vs DOSEF Comparison Chart
Loading...
ADAG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAG vs. DOSEF commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAG is a Hold and DOSEF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (ADAG: $1.99 vs. DOSEF: $0.36)
Brand notoriety: ADAG and DOSEF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAG: 316% vs. DOSEF: 63%
Market capitalization -- ADAG: $93.75M vs. DOSEF: $1.63M
ADAG [@Biotechnology] is valued at $93.75M. DOSEF’s [@Biotechnology] market capitalization is $1.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAG’s FA Score shows that 0 FA rating(s) are green whileDOSEF’s FA Score has 0 green FA rating(s).

  • ADAG’s FA Score: 0 green, 5 red.
  • DOSEF’s FA Score: 0 green, 5 red.
According to our system of comparison, DOSEF is a better buy in the long-term than ADAG.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAG’s TA Score shows that 6 TA indicator(s) are bullish.

  • ADAG’s TA Score: 6 bullish, 4 bearish.

Price Growth

ADAG (@Biotechnology) experienced а +2.58% price change this week, while DOSEF (@Biotechnology) price change was +282.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

ADAG is expected to report earnings on Aug 27, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ADAG($93.7M) has a higher market cap than DOSEF($1.63M). DOSEF YTD gains are higher at: 158.861 vs. ADAG (0.000). DOSEF has higher annual earnings (EBITDA): -261.38K vs. ADAG (-31.51M). ADAG has more cash in the bank: 95.7M vs. DOSEF (931K). DOSEF has less debt than ADAG: DOSEF (0) vs ADAG (20.8M). ADAG has higher revenues than DOSEF: ADAG (816K) vs DOSEF (58.3K).
ADAGDOSEFADAG / DOSEF
Capitalization93.7M1.63M5,756%
EBITDA-31.51M-261.38K12,054%
Gain YTD0.000158.861-
P/E RatioN/AN/A-
Revenue816K58.3K1,400%
Total Cash95.7M931K10,279%
Total Debt20.8M0-
TECHNICAL ANALYSIS
Technical Analysis
ADAG
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 6 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 12 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ADAG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSXMX63.790.65
+1.03%
NYLI S&P 500 Index SIMPLE Class
DCLVX18.12N/A
N/A
Dunham Large Cap Value C
CLPCX12.16N/A
N/A
Catalyst Nasdaq-100 Hedged Equity C
WPVIX34.25N/A
N/A
Weitz Multi Cap Equity-Institutional Cl
PRJBX44.79N/A
N/A
PGIM Jennison Global Opportunities R2

ADAG and

Correlation & Price change

A.I.dvisor tells us that ADAG and ENTA have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ADAG and ENTA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAG
1D Price
Change %
ADAG100%
+4.74%
ENTA - ADAG
25%
Poorly correlated
+3.61%
IBO - ADAG
25%
Poorly correlated
-5.40%
CRDF - ADAG
23%
Poorly correlated
+7.18%
CYBN - ADAG
22%
Poorly correlated
+0.91%
IGC - ADAG
22%
Poorly correlated
+1.73%
More

DOSEF and

Correlation & Price change

A.I.dvisor tells us that DOSEF and MNPR have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DOSEF and MNPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DOSEF
1D Price
Change %
DOSEF100%
N/A
MNPR - DOSEF
24%
Poorly correlated
-2.38%
AKRO - DOSEF
23%
Poorly correlated
+0.63%
SGMT - DOSEF
21%
Poorly correlated
+16.32%
ADAG - DOSEF
21%
Poorly correlated
+4.74%
CLRPF - DOSEF
12%
Poorly correlated
+0.32%
More